Studies performed by Pettirossi et al to confirm the mechanism of BRAF inhibition in HCL. (Left) Before and (right) after BRAF inhibition with vemurafenib. From top to bottom: (A) phosphorylated ERK and MEK; (B) HCL-related genes with large differences in expression before and after vemurafenib (each column, 1 of 6 patients); (C) bone marrow immunohistochemistry for cyclin D1 and CD20; (D) flow cytometry of the bone marrow aspirate; and (E) confocal microscopy of HCL cells showing loss of hairy morphology. See Figures 1A, 2B, 3A,C, and 4C-D in the article by Pettirossi et al that begins on page 1207.

Studies performed by Pettirossi et al to confirm the mechanism of BRAF inhibition in HCL. (Left) Before and (right) after BRAF inhibition with vemurafenib. From top to bottom: (A) phosphorylated ERK and MEK; (B) HCL-related genes with large differences in expression before and after vemurafenib (each column, 1 of 6 patients); (C) bone marrow immunohistochemistry for cyclin D1 and CD20; (D) flow cytometry of the bone marrow aspirate; and (E) confocal microscopy of HCL cells showing loss of hairy morphology. See Figures 1A, 2B, 3A,C, and 4C-D in the article by Pettirossi et al that begins on page 1207.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal